

12 June 2025

## EVE Completes Nextract Acquisition

- Acquisition of Nextract Pty Ltd completed
- Nextract lead product targets the US\$5.3<sup>1</sup> billion erectile dysfunction market with a therapeutic onset targeted within 15 minutes
- Nextract is developing proprietary oral strip and chewable dosage formats for well-established active pharmaceutical ingredients (APIs), including Tadalafil, which has been safely used for over 20 years
- Second product targeting dysmenorrhea (US\$10.9<sup>2</sup> billion market) progressing on a parallel timeline, leveraging alternative manufacturing pathway for commercial entry
- \$1 million Placement completed at \$0.036 per share
- Share Purchase Plan (SPP) now open to raise up to \$500,000 on same terms as the Placement
- Stuart Gunzburg appointed Chief Scientific Officer and Executive Director
- Board transition completed: Carlos Jin retires, Bill Fry becomes Non-Executive Director

**EVE Health Group (ASX:EVE, EVE or the Company)**, today announces that it has completed the acquisition of 100% of Nextract Pty Ltd ("Nextract"), a biotech company focused on proprietary solubility-enhancing drug delivery systems for regulated pharmaceutical and nutraceutical products.

The transaction has been settled through the issue of 83,333,333 fully paid ordinary shares in EVE at a post-consolidation price of \$0.036 per share, following shareholder approval on 29 May 2025.

Concurrently, the Company has also completed a \$1 million Placement to sophisticated and professional investors, issuing 27,777,778 shares at the same price. Proceeds will fund Nextract's integration, initial manufacturing scale-up, and regulatory submissions.

### Board and management changes

Nextract founder, Dr Stuart Gunzburg has been formally appointed the Chief Scientific Officer and Executive Director of EVE. Dr Gunzburg brings deep expertise in formulation technologies to lead the Company's R&D and product development efforts.

As part of the completion of the Nextract transaction, Mr Carlos Jin has retired from the Board effective today. Mr Bill Fry, who has served as Managing Director since 2009, has transitioned to a Non-Executive Director role. The Board extends its sincere thanks to Mr Fry and Mr Jin for their contributions and wishes them well in their future endeavours.

<sup>1</sup> Coherent Market Insights - <https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200>

<sup>2</sup> IMARC Group, Dysmenorrhea Market Outlook 2025–2035 – [www.imarcgroup.com/dysmenorrhea-market-outlook](https://www.imarcgroup.com/dysmenorrhea-market-outlook)

As previously announced, Mr Damian Wood will take on the role of Chief Executive Officer of EVE upon completion of the transaction and following the conclusion of his current contractual commitments. Mr Wood brings significant expertise across clinical formulation, regulatory approvals, and commercialisation strategy.

**Chairman Rodney Hannington** added:

“This is a pivotal day for EVE. With Nextract now part of the Group, we are positioned to accelerate our transition into a serious player in regulated healthcare,” said Mr Hannington. “Our delivery technology is designed to solve real-world problems in patient compliance and onset of action.”

### **Share Purchase Plan**

To provide eligible existing shareholders the opportunity to participate on the same terms, the Company has today opened its Share Purchase Plan (SPP) to raise up to \$500,000. Full SPP details are available in the SPP Offer Booklet/Prospectus dispatched separately.

#### *Timetable*

<b>Event</b>	<b>Date</b>
Record Date for Share Purchase Plan	11 April 2025
Dispatch of Share Purchase Plan Booklet and Offer Open	12 June 2025
Closing Date for Share Purchase Plan	23 June 2025
Announcement of Results of Share Purchase Plan and Issue of Share Purchase Plan Shares	26 June 2025

Authorised for release by the Board of Directors.

— ENDS —

#### **Company enquiries**

+61 8 6465 5500

[info@evehealthgroup.com.au](mailto:info@evehealthgroup.com.au)

#### **About EVE Health Group**

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit [www.evehealthgroup.com.au](http://www.evehealthgroup.com.au) and follow us on LinkedIn.